N4P Stock Price: N4 Pharma PLC holds onto high ground amid coronavirus progress, Phase 3 plans
|N4 Pharma PLC's shares have hit 16 pence, doubling from 7.95, the previous closing price. The British company reported promising results in its coronavirus research. LON: NAP continues fluctuating at high volatility.
Update: After closing at 12.50 pence in Tuesday's session – off the peak of 16 but more than 50% up on the day – LONG: N4P continues garnering attention and has room to extend its gains on Wednesday. Investors are eager for anything that helps alleviate the immense health and economic pressures caused by COVID-19. That has sent S&P 500 briefly above its record high.
The pharma firm reported positive COVID-19 Vitro study results using – Nuvex loaded with coronavirus plasmid transfected human embryonic kidney cells in vitro and it induced expression of spike protein cells.
The company is now advancing directly to the third stage of its COVID-19 project. Shares of pharma firms in the US and in the UK have been surging in response to publications about advances in their coronavirus studies.
Russian President Vladimir Putin announced his country registered the world's first coronavirus vaccine – yet scientists remain skeptical about the achievement, as it lacks a Phase 3 test.
N4 Pharma plc share price
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.